JUL 1·SEC EDGARLow
Shefferman Jesse sold $882K of TARA
Shefferman Jesse (CEO and President) sold 215,687 shares of Protara Therapeutics, Inc. (TARA) at $4.09 ($0.88M total) on 2026-06-29.
StockNASDAQ · US · USDHealthcare · Biotechnology
$TARA
Protara Therapeutics, Inc.
Price · $TARAvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $TARA in the last 7 days.
Insider · 30dAll trades →
No SEC Form 4 filings for $TARA in the last 30 days.
See all $TARA insider activity →Top stories · $TARAMore →
JUN 29·SEC EDGAR 8-K
Protara Therapeutics, Inc. (TARA): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Protara Therapeutics, Inc. (TARA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001359931 0001359931 2026-06-26 2026-06-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
JUN 15·SEC EDGAR 8-K
Protara Therapeutics, Inc. (TARA): Submission of Matters to a Vote of Security Holders
Protara Therapeutics, Inc. (TARA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001359931 0001359931 2026-06-12 2026-06-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
TARA sentiment & insider activity
Recent TARA coverage spans financial news, corporate actions and insider activity.
What's driving TARA
Routine insider selling by the CEO; may slightly affect sentiment but provides no new operational or financial catalyst.
Board/officer reshuffle may affect near-term clinical execution and internal accountability, but no financial guidance or trial results were provided.
Shareholder votes confirm corporate governance/capital-structure changes (authorized share increase, equity plan amendment, officer exculpation).
Oppenheimer's upgrade of Protara Therapeutics (TARA) to a $28 target from $25, supported by positive Phase 2 trial data, suggests a bullish outlook. The stock's sentiment is bullish with a high confidence level, indicating potential near-term upside.
Protara Therapeutics announced interim results from its Phase 2 trial, indicating ongoing clinical progress. The news has a modest positive sentiment, with a somewhat bullish market sentiment score.
alphai scores every news story that mentions TARA with an AI model for sentiment and relevance, and aggregates insider trades from Protara Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $TARA
Score
Shefferman Jesse sold $882K of TARA
Shefferman Jesse (CEO and President) sold 215,687 shares of Protara Therapeutics, Inc. (TARA) at $4.09 ($0.88M total) on 2026-06-29.
2 min readProtara Therapeutics, Inc. (TARA): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Protara Therapeutics, Inc. (TARA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001359931 0001359931 2026-06-26 2026-06-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
2 min readProtara Therapeutics, Inc. (TARA): Submission of Matters to a Vote of Security Holders
Protara Therapeutics, Inc. (TARA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001359931 0001359931 2026-06-12 2026-06-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
3 min readOppenheimer Adjusts Protara Therapeutics PT to $28 From $25, Maintains Outperform Rating
Oppenheimer has increased its price target for Protara Therapeutics (TARA) to $28 from $25, while reiterating an Outperform rating on the stock. This adjustment comes after the company announced positive updated 12-month data earlier in May, demonstrating durable responses in a Phase 2 trial for TARA-002, its lead investigational therapy for non-muscle invasive bladder cancer.
2 min read
What's Going On With Protara Therapeutics Stock Wednesday? - Protara Therapeutics (NASDAQ:TARA)
Protara Therapeutics Inc. ( NASDAQ:TARA ) on Wednesday announced interim results from its ongoing Phase 2 open-label STARBORN-1 trial assessing intracystic injection of TARA-002.
4 min readProtara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations on Wednesday, November 19, 2025
NEW YORK, Nov. 18, 2025 ( GLOBE NEWSWIRE ) -- Protara Therapeutics, Inc. ( Nasdaq: TARA ) , a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced it will host a conference call and live webcast at 8:30 a.m.
2 min read
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) - Protara Therapeutics (NASDAQ:TARA)
NEW YORK, Oct. 01, 2025 ( GLOBE NEWSWIRE ) -- Protara Therapeutics, Inc. ( NASDAQ:TARA ) ( "Protara" or the "Company" ) , a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the recent grants of inducement non-qualified ...
2 min readProtara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4)
NEW YORK, Aug. 01, 2025 ( GLOBE NEWSWIRE ) -- Protara Therapeutics, Inc. ( Nasdaq: TARA ) ( "Protara" or the "Company" ) , a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the recent grants of inducement non-qualified ...
2 min readAegle Therapeutics Names Industry Veteran Scott Braunstein, M.D. as Chairman of the Board
BOSTON, July 15, 2025 ( GLOBE NEWSWIRE ) -- Aegle Therapeutics, a clinical-stage dermatology-focused biopharmaceutical company developing novel therapies for those living with rare and severe skin diseases, today announced the appointment of Scott Braunstein, M.D., as Chairman of the Board.
2 min readProtara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4)
NEW YORK, July 01, 2025 ( GLOBE NEWSWIRE ) -- Protara Therapeutics, Inc. ( Nasdaq: TARA ) ( "Protara" or the "Company" ) , a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the recent grants of inducement non-qualified ...
2 min read